C3a receptor antagonist therapy is protective with or without thrombolysis in murine thromboembolic stroke.

Saif AhmadChirayu PandyaAdam KindelinKanchan BhatiaRafay ChaudharyAlok Kumar DwivediJennifer M EschbacherQiang LiuMichael F WatersMd Nasrul HodaAndrew F Ducruet

Published in: British journal of pharmacology (2020)

We conclude that SB290157 is safe and effective with and without late IVT following TE stroke. Therefore, C3a receptor antagonist therapy represents a promising candidate for clinical translation in stroke, particularly as an adjuvant to IVT.

Keyphrases

atrial fibrillation
early stage
cerebral ischemia
acute ischemic stroke
mesenchymal stem cells
bone marrow
cell therapy
smoking cessation